

Ent
Q'7
The reaction mixture was treated with dimethylsulfide and concentrated to obtain the aldehyde. To the mixture of this aldehyde and KLH in phosphate buffer was added sodium cyanoborohydride and stirred for 30h. After purified by dialysis using PBS(-), the objective glycoprotein antigen was obtained.

Clean copies of the above-amended paragraphs are attached hereto.

IN THE CLAIMS

Please cancel claims 5-7 and 9-16 in their entirety and without prejudice.

Please enter the following new claims:

--17. (New) The non-mucin type synthetic compound or carrier conjugated compound thereof of claim 1, wherein A is sialic acid and/or its derivatives and B is OH.

Q'8
18. (New) The non-mucin type synthetic compound or carrier conjugated compound thereof of claim 2, wherein A is sialic acid and/or its derivatives and B is OH.

19. (New) The non-mucin type synthetic compound or carrier conjugated compound thereof of claim 3, wherein A is sialic acid and/or its derivatives and B is OH.

20. (New) The non-mucin type synthetic compound or carrier conjugated compound thereof of claim 4, wherein A is sialic acid

Cat
Q18
and/or its derivatives and B is OH.

21. (New) The non-mucin type synthetic compound or carrier conjugated compound thereof of claim 1, wherein A is OH and B is galactose and/or its derivatives.

22. (New) The non-mucin type synthetic compound or carrier conjugated compound thereof of claim 2, wherein A is OH and B is galactose and/or its derivatives.

23. (New) The non-mucin type synthetic compound or carrier conjugated compound thereof of claim 3, wherein A is OH and B is galactose and/or its derivatives

24. (New) The non-mucin type synthetic compound or carrier conjugated compound thereof of claim 4, wherein A is OH and B is galactose and/or its derivatives

25. (New) The non-mucin type synthetic compound or carrier conjugated compound thereof of claim 1, wherein both A and B are OH.

26. (New) The non-mucin type synthetic compound or carrier conjugated compound thereof of claim 2, wherein both A and B are OH.

27. (New) The non-mucin type synthetic compound or carrier conjugated compound thereof of claim 3, wherein both A and B are OH.

28. (New) The non-mucin type synthetic compound or carrier conjugated compound thereof of claim 4, wherein both A and B are OH.

29. (New) Immunotherapy using the non-mucin type synthetic

Ant
Q'8
compound or carrier conjugated compound thereof of claim 1.

30. (New) Immunotherapy using the non-mucin type synthetic compound or carrier conjugated compound thereof of claim 2.

31. (New) Immunotherapy using the non-mucin type synthetic compound or carrier conjugated compound thereof of claim 3.

32. (new) Immunotherapy using the non-mucin type synthetic compound or carrier conjugated compound thereof of claim 4.

33. (New) Monoclonal antibodies prepared using the non-mucin type synthetic compound or carrier conjugated compound thereof of claim 1.

34. (New) Monoclonal antibodies prepared using the non-mucin type synthetic compound or carrier conjugated compound thereof of claim 2.

35. (New) Monoclonal antibodies prepared using the non-mucin type synthetic compound or carrier conjugated compound thereof of claim 3.

36. (New) Monoclonal antibodies prepared using the non-mucin type synthetic compound or carrier conjugated compound thereof of claim 4.

37. (New) Antitumor agents containing the non-mucin type synthetic compound or carrier conjugated compound thereof of claim 1 as an active ingredient.

38. (New) Antitumor agents containing the non-mucin type synthetic compound or carrier conjugated compound thereof of claim 2 as an active ingredient.

39. (New) Antitumor agents containing the non-mucin type

20
Q18
synthetic compound or carrier conjugated compound thereof of
claim 3 as an active ingredient.

40. (New) Antitumor agents containing the non-mucin type
synthetic compound or carrier conjugated compound thereof of
claim 4 as an active ingredient.

41. (New) Tumor immunostimulant containing the non-mucin
type synthetic compound or carrier conjugated compound thereof of
claim 1 as an active ingredient.

42. (New) Tumor immunostimulant containing the non-mucin
type synthetic compound or carrier conjugated compound thereof of
claim 2 as an active ingredient.

43. (New) Tumor immunostimulant containing the non-mucin
type synthetic compound or carrier conjugated compound thereof of
claim 3 as an active ingredient.

44. (New) Tumor immunostimulant containing the non-mucin
type synthetic compound or carrier conjugated compound thereof of
claim 4 as an active ingredient.

45. (New) Anti human immunodeficiency virus (HIV) agents
containing the non-mucin type synthetic compound or carrier
conjugated compound thereof of claim 1 as an active ingredient.

46. (New) Anti human immunodeficiency virus (HIV) agents
containing the non-mucin type synthetic compound or carrier
conjugated compound thereof of claim 2 as an active ingredient.

47. (New) Anti human immunodeficiency virus (HIV) agents
containing the non-mucin type synthetic compound or carrier
conjugated compound thereof of claim 3 as an active ingredient

Ent
P's

48. (New) Anti human immunodeficiency virus (HIV) agents containing the non-mucin type synthetic compound or carrier conjugated compound thereof of claim 4 as an active ingredient.

49. (New) An immunostimulant for human immunodeficiency virus (HIV) containing the non-mucin type synthetic compound or carrier conjugated compound thereof of claim 1 as an active ingredient.

50. (New) An immunostimulant for human immunodeficiency virus (HIV) containing the non-mucin type synthetic compound or carrier conjugated compound thereof of claim 2 as an active ingredient.

51. (New) An immunostimulant for human immunodeficiency virus (HIV) containing the non-mucin type synthetic compound or carrier conjugated compound thereof of claim 3 as an active ingredient.

52. (New) An immunostimulant for human immunodeficiency virus (HIV) containing the non-mucin type synthetic compound or carrier conjugated compound thereof of claim 4 as an active ingredient.

53. (New) A therapeutic method for tumor treatment using the non-mucin type synthetic compound or carrier conjugated compound thereof of claim 1 as an active ingredient.

54. (New) A therapeutic method for tumor treatment using the non-mucin type synthetic compound or carrier conjugated compound thereof of claim 2 as an active ingredient.

55. (New) A therapeutic method for tumor treatment using